Bioterápico 17DH de Trypanosoma cruzi aumenta a apoptose em camundongos experimentalmente infectados / Biotherapic of Trypanosoma cruzi 17d increases apoptosis in experimentally infected mice

Introduction: the mechanism of action of ultradiluted medicines has not yet been established[1,3]. Many basic research studies have focused on isopathic models using in vitro or in vivo designs [4,5]. Recent studies indicate that an ultradiluted (isopathic) antigen can transfer signals to the immune system and modulate its response when an organism is challenged against this same antigen [6]. Some studies on experimental infection of mice by T. cruzi identified apoptotic cells and showed that the increase of their number is associated with an increase also in the number of parasites in the blood of the infected animals, while blockage of apoptosis can be the target of therapeutic intervention [7,8].Conclusion: these results show that apoptosis is increased in animals treated with biotherapic of T. cruzi 17d.n(AU)

Introdução: O mecanismo de ação de medicamentos ultradiluídos ainda não está elucidado [1-3]. Muitos estudos em pesquisas básicas concentraram-se nos modelos de isopatia, utilizando protocolos in vivo ou in vitro [4,5]. Estudos recentes relatam que um antígeno ultradiluído (isopático) pode transferir sinais para o sistema imunológico e modular a sua resposta quando o organismo é desafiado contra este antígeno [6]. Outros trabalhos mostraram que na infecção experimental de camundongos pelo T. cruzi foram detectadas células apoptóticas e que um aumento das células apoptóticas está relacionado ao aumento da parasitemia em animais infectados e que o bloqueio da apoptose pode ser alvo de intervenção terapêutica [7,8].Conclusão: A apoptose está aumentada em animais tratados com bioterápico 17DH de T. cruzi e infectados pelo protozoário.(AU)

Bioterápico 17DH de Trypanosoma cruzi diminui alterações histopatológicas em camundongos infectados pelo protozoário / Biotherapic of Trypanosoma cruzi 17x controlled histopathological alterations in mice infected by this protozoon

Introduction: about 10 million people worldwide suffer from Chagas? disease [1]. The World Health Organization (WHO) has explicitly acknowledged the significance of this condition and supports the use of Complementary and Alternative Medicine by health systems integrated with conventional treatments. Even so, one century after its discovery it still represents a global challenge [1,2]. Biotherapics are ultradiluted medicines and the infection of mice by Trypanosoma cruzi is an excellent model to understand their effect [3,4]. At 8 weeks, mice are physiologically more developed than at age 4 weeks, including a more competent immune system [5].Conclusion: there is a difference in the effect of the ultradiluted medicine between mice 4- and 8-week old. Eight-week old animals treated with biotherapic exhibited lower tissue parasitism, which is the opposite of what was observed in 4-week old animals.(AU)